Maropost bolsters product leadership team to accelerate innovation and growth
Maropost, the commerce software suite built for fast-growing commerce brands, announces two significant appointments to its senior leadership team: Tim Schulz joins as VP of Product, Commerce Cloud, and Alessandra "Alex" Jacques steps in as VP of Product, Marketing Cloud.
"I founded Maropost to disrupt a crowded market, and with Tim and Alex on board, we are aggressively pursuing that vision," said Maropost Chairman and CEO Ross Andrew Paquette. "We're building a single platform that puts fast-growing retailers in control of their customer journeys, from hyper-personalized marketing to in-store and online purchases through exceptional service.
"Brands will use Maropost to create and manage product catalogs, centrally design and deploy promotions across all their channels, build engaging storefronts, and deliver personalized shopping experiences from one data set, in one nerve center."
Paquette is confident Maropost will achieve this mission. "We're not just another player in the market; we're here to redefine it. Watch closely: We're about to show what's possible when ingenuity meets determination."
About the New Appointees
Alex Jacques brings deep product management expertise from her roles at Terminus and Cheetah Digital. A certified CSM and CSPO, she excels at leading highly functional scrum teams, managing multiple platforms, and driving customer experience strategies. Her marketing technology prowess will shape the future of Marketing Cloud.
Tim Schulz is a seasoned product and technology leader with a track record of delivering outstanding results. As Head of Product at Magento and VTEX, he built products that enabled mid-market and enterprise retailers to scale their businesses globally and respond to shifts in the industry. At BigCommerce, he led Product & Engineering and grew revenue to over $100 million ARR in 24 months while launching strategic partnerships with top tech companies, including Facebook, Twitter, Google, and Alibaba.
Tim was also a top 5% performer at Google, where he led global platform partnerships for Google Shopping and drove 40 full-cycle enterprise deals across product lines. At Maropost, Tim will direct the development of future commerce products.
"We're thrilled to welcome Alex and Tim to the Maropost team," said Sean Brady, COO and President of Maropost. "Their extensive product expertise, proven leadership, and passion for delivering exceptional customer experiences will help us realize our vision of a unified platform that helps them grow, scale, and drive real value from their marketing, commerce, and service efforts."
About Maropost
Only Maropost unites the commerce tools and insights growing brands need to engage customers and scale their business. Built on unified customer data and an enterprise-grade infrastructure, Maropost offers a complete, connected suite of marketing, merchandising and search, customer service, ecommerce, and retail solutions.
Since its founding in 2011, Maropost has made multiple appearances on Deloitte's Technology Fast 500 list and G2's leaderboard. A global company, Maropost proudly serves 5,000+ leading commerce brands across North America, Australia, and Europe, including Victoria Beckham, Sandro Paris, Untuckit, Scott Sports, James Perse, and Fujifilm.
Learn more at www.maropost.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521528910/en/
Contact information
Rob Wade
(888) 438-3152
press@maropost.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom